文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

体外免疫调节治疗与ICU新冠患者的临床结局

Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients.
PubMed 文献 · Crit Care Explor · 2022-05-19
一句话结论在合并多器官衰竭的ICU新冠患者中,选择性细胞处理装置(SCD)治疗未发生装置相关严重不良事件,60天死亡率50%,对照队列为81%。

本研究报告一项双中心、前瞻性、单臂治疗临床试验,在2020年9月至2021年7月两个学术医学中心的ICU中,评估选择性细胞处理装置(SCD)用于22例需要机械通气的ARDS新冠患者的安全性和临床结局。SCD整合入连续肾脏替代治疗体外血路,最长治疗10天,以自体白细胞细胞处理调节COVID-19高炎症状态。治疗未出现装置相关严重不良事件,流式细胞术显示选择性清除高活化循环白细胞,IL6、IL15、IL10和可溶性ST2等8种细胞因子和生物标志物血浆水平显著降低;治疗期间白细胞增多和Po2/Fio2比值显著改善,对照组未观察到。SCD治疗组60天死亡率为50%,对照队列为81%;按方案接受超过96小时SCD治疗的受试者死亡率进一步降至31%(p<0.012)。

要点

  • 在需要机械通气的ICU新冠ARDS患者中,SCD整合入CRRT体外血路最长治疗10天,未发生装置相关严重不良事件。
  • SCD治疗组60天死亡率为50%,同期前瞻性注册CRRT试验选取的16例对照为81%。
  • 按方案接受超过96小时SCD治疗的受试者死亡率进一步降至31%(p<0.012)。
  • 治疗期间白细胞增多和Po2/Fio2比值显著改善,对照组未观察到。
  • 治疗显著降低IL6、IL15、IL10和可溶性ST2等8种与新冠死亡预测相关的细胞因子和生物标志物血浆水平。

适用人群与场景

  • ICU中需要机械通气的急性呼吸窘迫综合征COVID-19患者。
  • 干预组几乎全部(除1例外)合并急性肾损伤并需要连续肾脏替代治疗(CRRT)。
  • 纳入16例符合入组标准的受试者作为同期对照,来自一项同期前瞻性注册CRRT试验。

处置流程与药物剂量

  • 将选择性细胞处理装置(SCD)整合入连续肾脏替代治疗体外血路,最长治疗10天,以提供自体白细胞细胞处理,调节COVID-19高炎症状态。

研究设计与关键结果

  • 研究设计为双中心、前瞻性、单臂治疗临床试验,在2020年9月至2021年7月两个学术医学中心的ICU进行,干预组22例,对照组16例。
  • SCD治疗未发生装置相关严重不良事件;流式细胞术显示选择性清除高活化循环白细胞。
  • 治疗显著降低IL6、IL15、IL10和可溶性ST2等8种与新冠死亡预测相关的细胞因子和生物标志物血浆水平。
  • 治疗期间白细胞增多和Po2/Fio2比值显著改善,对照组未观察到。
  • SCD治疗组60天死亡率为50%,对照队列为81%。
  • 按方案接受超过96小时SCD治疗的受试者死亡率进一步降至31%(p<0.012)。

证据类型、等级与局限

  • 证据类型:双中心、前瞻性、单臂治疗临床试验,对照组为同期前瞻性注册CRRT试验中选取的16例受试者。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于尽管接受最大化药物和器官支持干预仍进展为多器官衰竭的COVID-19 ICU患者,SCD作为挽救治疗可改善临床结局。
  • 作者认为,这种自体白细胞细胞处理技术可能为治疗COVID-19持续不缓解的高炎症提供新方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: To evaluate safety and clinical outcomes of extracorporeal immunomodulation treatment with a selective cytopheretic device (SCD) in COVID-19 ICU patients with multiple organ failure.

DESIGN: Two-center, prospective, single-arm treatment clinical trial.

SETTING: ICUs at two academic medical centers between September 2020 and July 2021.

PATIENTS: Twenty-two COVID-10 patients in the ICU with acute respiratory distress syndrome who required mechanical ventilation. Nearly all included patients in the intervention group except one had acute kidney injury requiring continuous renal replacement therapy (CRRT). Sixteen subjects meeting enrollment criteria were selected as contemporaneous controls from a concurrent prospective registry CRRT trial.

INTERVENTION: Treatment with an SCD integrated into a continuous renal replacement extracorporeal blood circuit for up to 10 days to provide autologous leukocyte cell processing to immunomodulate the hyperinflammatory disease state of COVID-19.

MEASUREMENTS AND MAIN RESULTS: SCD treatment in COVID-19 ICU patients with multiple organ failure demonstrated an acceptable safety profile with no device-related serious adverse events. Treatment of these patients resulted in the selective removal of highly activated circulating leukocytes as determined by flow cytometry. Significant reductions were observed in the elevated plasma levels of eight cytokines and biomarkers, including interleukin (IL)6, IL15, IL10, and soluble ST2, which are predictive of mortality in COVID-19 patients. Significant improvements of leukocytosis and Po2/Fio2 ratios occurred during treatment not observed in the control group. SCD-treated subjects had a reduction in 60-day mortality of 50% compared with 81% in the control cohort. The subjects who received greater than 96 hours of SCD treatment, per protocol, had a further reduction in mortality to 31% (p < 0.012).

CONCLUSIONS: Extracorporeal immunomodulation therapy with an SCD demonstrated safety without any device-related serious adverse events. As a rescue therapy in COVID-19 ICU patients progressing to multiple organ failure despite maximal pharmacologic and organ support interventions, SCD treatment resulted in improved clinical outcomes. This autologous leukocyte cell processing technology may provide a new approach in the treatment of unremitting hyperinflammation of COVID-19.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Yessayan LT, Neyra JA, Westover AJ, et al. Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients. Crit Care Explor. 2022. PMID: 35620768. doi:10.1097/CCE.0000000000000694

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。